What Is the Stage 4 Endometrial Cancer Survival Rate?

Five-year survival for stage 4 endometrial cancer has historically hovered around 15 to 20 percent, with a median survival of roughly one year from diagnosis in older studies. Those numbers, while still sobering, increasingly undersell the picture for many patients diagnosed today. Immunotherapy, molecular profiling, and more aggressive surgical approaches have reshaped outcomes for certain subgroups so dramatically that a single survival statistic no longer captures the range of what stage 4 patients actually experience.

What Stage 4 Actually Means

Endometrial cancer reaches stage 4 when it has spread beyond the uterus and cervix. Under the 2023 FIGO staging system, stage 4 is now divided into three substages: IVA, where the cancer has infiltrated the bladder or rectal lining; IVB, where it has spread to surfaces inside the pelvis but outside the reproductive organs (extrapelvic peritoneal metastasis); and IVC, where it has reached distant organs like the lungs, liver, bones, or brain.¹ This distinction matters because a patient with cancer on the bladder surface (IVA) faces a different situation than someone with liver or lung metastases (IVC), even though both are grouped under “stage 4.”

Where the Headline Survival Numbers Come From

The often-cited five-year survival of about 15 percent comes from studies that predate many current treatments. One ten-year review found a median survival of 12 months and a five-year survival of 15 percent for stage IV patients.² For aggressive histologic subtypes like uterine serous carcinoma, five-year survival for stage IVB disease has been reported at under 20 percent.³ These figures reflect averages across a broad population, lumping together patients who had surgery with those who did not, patients with slow-growing tumors alongside those with rapidly progressing ones, and people treated in earlier decades alongside more recently diagnosed patients. A five-year survival rate is also a lagging indicator; it reflects outcomes for patients diagnosed five or more years ago, meaning it cannot account for therapies approved in the last few years.

How Surgery Changes the Outlook

For patients who are well enough to undergo it, the extent of surgical tumor removal is one of the strongest predictors of survival in stage 4 endometrial cancer. The goal of cytoreductive surgery is to leave behind as little visible tumor as possible. In one study, patients who had optimal surgery (no remaining tumor larger than 1 cm) survived a median of about 34 months, compared to 11 months for those left with larger residual disease.⁴ Among optimally debulked patients, those with only microscopic residual disease fared even better.

A more recent systematic review and meta-analysis confirmed this pattern across ten studies: patients who had complete or optimal cytoreductive surgery had survival measured in roughly 18 to 48 months, while those with incomplete surgery survived 7 to 19 months. The pooled analysis found that complete or optimal surgery reduced the risk of death by about 62 percent compared to incomplete surgery.⁵ Not every patient is a candidate for aggressive surgery, but for those who are, it substantially shifts the survival curve.

Standard Chemotherapy

For most patients with advanced endometrial cancer, the backbone of systemic treatment has been the combination of carboplatin and paclitaxel. A large phase III trial established this regimen as the global first-line standard after showing it was equally effective but less toxic than a three-drug combination. Median overall survival in that trial was about 37 months with carboplatin and paclitaxel.⁶ That number may seem surprisingly high compared to the older five-year survival statistics, and the difference partly reflects the fact that this trial included patients with advanced-stage disease who were healthy enough to receive chemotherapy and who often had some degree of surgical debulking first.

Chemotherapy alone is no longer the end of the conversation for most stage 4 patients. It now serves as the platform onto which newer immunotherapy agents are added.

The Immunotherapy Shift

The biggest change in stage 4 endometrial cancer treatment in the past several years has been the addition of immune checkpoint inhibitors to chemotherapy. The benefits are largest for a specific group of patients: those whose tumors have a feature called mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H), which occurs in roughly a quarter to a third of endometrial cancers. These tumors accumulate mutations at a high rate, which makes them more visible to the immune system when given the right drug.

In the RUBY trial, adding dostarlimab (an anti-PD-1 immunotherapy drug) to standard chemotherapy produced dramatic results in the dMMR/MSI-H population: estimated progression-free survival at 24 months was about 61 percent with dostarlimab versus 16 percent with placebo. Overall survival at 24 months across the full study population was about 71 percent with dostarlimab compared to 56 percent with placebo.⁷

The NRG GY018 trial found a parallel story with pembrolizumab, another checkpoint inhibitor. Adding pembrolizumab to chemotherapy improved progression-free survival in both dMMR and mismatch repair-proficient (pMMR) patients, though the benefit was stronger in the dMMR group.⁸ A systematic review of pembrolizumab trials reinforced that the survival improvements are most consistent in dMMR patients, while the benefit in pMMR tumors remains more modest.⁹

For patients whose tumors are dMMR/MSI-H, immunotherapy plus chemotherapy has fundamentally changed the expected trajectory. A 24-month progression-free survival of 61 percent is a different world from the 15 percent five-year survival of earlier decades, though longer follow-up is still needed to know how these early gains translate into cure rates.

Options for Tumors That Do Not Respond to Immunotherapy Alone

Patients with pMMR tumors, which make up the majority of endometrial cancers, do not respond as robustly to checkpoint inhibitors by themselves. For previously treated patients whose cancer has progressed, the combination of lenvatinib (a targeted drug that blocks blood vessel growth and other tumor-supporting pathways) with pembrolizumab has been an important option. In a pivotal trial, lenvatinib plus pembrolizumab improved median overall survival to about 18 months compared to roughly 11 months with chemotherapy alone in the overall population, and about 17 months versus 12 months specifically in the pMMR group.¹⁰

However, when lenvatinib plus pembrolizumab was tested as a first-line treatment (competing against standard chemotherapy rather than following it), the results were less impressive. In a phase III trial, median progression-free survival was similar between the combination and chemotherapy in pMMR patients, and the study did not meet its primary statistical goals.¹¹ This combination remains most clearly useful in the second-line setting, after chemotherapy has already been tried.

For patients with low-grade, slow-growing endometrial cancers that express hormone receptors, hormonal therapy remains an option. Response rates range from about 9 to 33 percent, and the approach is appealing for patients who cannot tolerate more aggressive treatments.¹²

Why Molecular Subtype Can Matter More Than Stage

One of the most important shifts in endometrial cancer is the recognition that molecular subtype predicts outcomes at least as powerfully as stage or histology. Tumors are now classified into four molecular groups based on patterns in their DNA. Two of these groups are especially relevant to stage 4 patients.

Tumors with mutations in the POLE gene tend to have the best prognosis across all stages, with a dramatically lower risk of progression and death. Pooled data show that POLE-mutated tumors carry roughly one-fifth to one-third the risk of dying compared to molecularly unclassified tumors.¹³ These tumors are uncommon in stage 4 disease, but when they do appear, they tend to behave more favorably.

At the other end of the spectrum, tumors with p53 mutations (sometimes called the “copy-number high” subtype) have the worst prognosis. Pooled analyses found that these tumors carried roughly three to five times the risk of death compared to other molecular subtypes.¹⁴ P53-mutant tumors overlap heavily with aggressive histologic types like serous carcinoma and are overrepresented in stage 4 disease.¹⁵

The practical takeaway is that two patients both diagnosed with stage 4 endometrial cancer can have vastly different expected outcomes depending on their tumor’s molecular profile. A dMMR/MSI-H tumor is more likely to respond to immunotherapy. A POLE-mutated tumor may behave better than its stage would suggest. A p53-mutant tumor demands the most aggressive approach available and still carries a tougher prognosis. Molecular testing is now standard practice for advanced endometrial cancer, and asking about it is reasonable for any patient diagnosed with stage 4 disease.

Where the Cancer Has Spread

Not all distant metastases are equal. In a large database study of nearly 3,000 women with stage IV endometrial cancer, lung was the most common site of distant spread. Using brain metastasis as the reference point (the worst category), patients with metastases to the liver, lung, or bone all had somewhat longer survival.¹⁶ Having more than one site of distant spread was independently associated with shorter survival compared to having a single metastatic site.

A separate analysis of endometrial cancer patients with liver metastases found that age over 60, non-endometrioid histology, not receiving surgery, not receiving chemotherapy, and having additional metastases in the lung, brain, or bone were all independent risk factors for worse outcomes.¹⁷ These findings reinforce how much individual disease anatomy shapes what stage 4 actually means for a given patient.

Conditional Survival Gets Better Over Time

One of the most encouraging aspects of survival statistics is a concept called conditional survival: the probability of surviving an additional five years given that you have already survived some period of time. For stage 4 endometrial cancer, these numbers improve substantially the longer a patient lives past diagnosis.

A Korean national registry study found that while the baseline five-year relative survival for distant-stage endometrial cancer was about 35 percent, this climbed to roughly 78 percent for patients who had already survived five years.¹⁸ A study focused on endometrioid-type tumors found a similar pattern: five-year conditional survival for women with stage IV high-grade endometrioid cancer was about 25 percent at diagnosis, but rose to roughly 36 percent after surviving one year, 49 percent after two years, and 75 percent after five years.¹⁹

These numbers are relevant for patients who have completed initial treatment and are wondering what comes next. The highest-risk period is the first one to two years after diagnosis. For those who make it through that window without recurrence, the statistical outlook brightens considerably.

Racial Disparities in Outcomes

Survival statistics for stage 4 endometrial cancer are not uniform across racial groups, and the disparities are not fully explained by differences in tumor biology or treatment access. A Gynecologic Oncology Group study pooling data from clinical trials, where treatment is standardized, found that Black women with advanced or recurrent endometrial cancer had shorter median survival than white women (about 11 months versus 12 months) and a 26 percent higher risk of death after adjusting for stage, grade, histology, and treatment.²⁰

A study within an equal-access military healthcare system, which removes insurance and cost barriers, found an even starker gap: Black women had a 64 percent higher adjusted risk of death after controlling for age, stage, histology, grade, and treatment. The disparity persisted even among women with early-stage and low-grade tumors, suggesting that biological and possibly systemic factors beyond treatment access play a role.²¹ Black women are also disproportionately diagnosed with aggressive histologic subtypes like serous carcinoma and at more advanced stages, which partly but not fully accounts for the gap.²²

These disparities mean that population-level survival statistics may not reflect the experience of every demographic group equally, and efforts to close these gaps remain a priority in gynecologic oncology research.

Frailty, Age, and Treatment Tolerance

Stage 4 endometrial cancer is most commonly diagnosed in women over 60, and a patient’s overall health and functional status can influence outcomes as much as tumor characteristics. Frailty, measured by factors like grip strength, walking speed, and weight loss, has been shown to predict outcomes independently of stage and grade. Women with at least one marker of frailty had roughly twice the risk of recurrence and shortened overall survival compared to non-frail patients, even after adjusting for other tumor-related factors.²³

This finding has practical implications. A patient who is frail may not tolerate aggressive surgery or full-dose chemotherapy, which limits access to the treatments most strongly associated with improved survival. For these patients, treatment plans often involve modified chemotherapy doses, single-agent approaches, hormonal therapy, or palliative radiation aimed at controlling symptoms like bleeding and pain rather than attempting cure. A systematic review of palliative pelvic radiation in gynecological cancers found encouraging results for managing bleeding (about 55 percent response) and pain control (about 70 percent response).²⁴

The Financial Side of Advanced Treatment

Extended treatment for advanced endometrial cancer carries financial costs that affect quality of life in their own right. A study of women with advanced or recurrent endometrial cancer found that about 38 percent reported moderate financial toxicity and roughly 8 percent reported severe financial toxicity. Financial strain was disproportionately reported by younger patients (under 65), Black and Hispanic women, unmarried women, and those with less education.²⁵ These costs include not only treatment itself but transportation, time off work, and the cascading expenses of long-term cancer care. Early conversations with a social worker or financial counselor at a cancer center can help identify assistance programs before debt accumulates.